News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novavax, Inc. (NVAX) to Present at BIT Life Sciences's 3rd World Congress of Vaccine



3/22/2011 6:19:38 AM

ROCKVILLE, Md., March 22, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, will give a keynote address at the 3rd World Congress of Vaccine on March 23rd, 2011 at the China National Convention Center in Beijing, China. Dr. Singhvi will be giving a presentation on Commercialization Strategies for Vaccines in Emerging Markets. In addition, John Trizzino, Senior VP - Business Development, will also give a presentation at the conference titled, The Value of Government Alliances for Effective Pandemic Preparedness.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like particles (VLPs) technology and single-use bioprocessing system enables rapid vaccine development and production where and when it's needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES